1. Sub-threshold depression and antidepressants use in a community sample: searching anxiety and finding bipolar disorder.
- Author
-
Carta MG, Tondo L, Balestrieri M, Caraci F, Dell'osso L, Di Sciascio G, Faravelli C, Hardoy MC, Lecca ME, Moro MF, Bhat KM, Casacchia M, and Drago F
- Subjects
- Adolescent, Adult, Aged, Anxiety Disorders complications, Anxiety Disorders drug therapy, Benzodiazepines therapeutic use, Bipolar Disorder complications, Depression complications, Depression diagnosis, Depression epidemiology, Female, Health Surveys statistics & numerical data, Humans, Italy epidemiology, Male, Middle Aged, Prevalence, Psychiatric Status Rating Scales statistics & numerical data, Antidepressive Agents therapeutic use, Anxiety Disorders epidemiology, Bipolar Disorder epidemiology, Depression drug therapy, Residence Characteristics statistics & numerical data
- Abstract
Background: To determine the use of antidepressants (ADs) in people with sub-threshold depression (SD); the lifetime prevalence of mania and hypomania in SD and the link between ADs use, bipolarity and anxiety disorders in SD., Study Design: community survey., Study Population: samples randomly drawn, after stratification from the adult population of municipal records., Sample Size: 4999 people from seven areas within six Italian regions. Tools: Questionnaire on psychotropic drug consumption, prescription; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Hamilton Depression Rating Scale (HAM-D); Mood Disorder Questionnaire (MDQ); Short Form Health Survey (SF-12). SD definition: HAM-D > 10 without lifetime diagnosis of Depressive Episode (DE)., Results: SD point prevalence is 5.0%. The lifetime prevalence of mania and hypomania episodes in SD is 7.3%. Benzodiazepines (BDZ) consumption in SD is 24.1%, followed by ADs (19.7%). In SD, positive for MDQ and comorbidity with Panic Disorder (PD) or Generalized Anxiety Disorders (GAD) are associated with ADs use, whereas the association between a positive MDQ and ADs use, without a diagnosis of PD or GAD, is not significant. Only in people with DE the well-being (SF-12) is higher among those using first-line antidepressants compared to those not using any medication. In people with SD no significant differences were found in terms of SF-12 score according to drug use., Conclusions: This study suggests caution in prescribing ADs to people with SD. In people with concomitant anxiety disorders and SD, it should be mandatory to perform a well-designed assessment and evaluate the presence of previous manic or hypomanic symptoms prior to prescribing ADs.
- Published
- 2011
- Full Text
- View/download PDF